Skip to main content
SpringerLink
Log in

Characteristics of Visual Electrophysiology in Retinal Toxicities

  • Chapter
  • First Online:
Handbook of Clinical Electrophysiology of Vision

  • 874 Accesses

Abstract

This chapter summarizes the application of electroretinogram, electrooculogram, and visual evoked potential in retinal toxicities caused by vigabatrin, hydroxychloroquine (Plaquenil), chloroquine, antipsychotics, cis-platinum, deferoxamine, digoxin, ethambutol, indomethacin, isotretinoin, ocular siderosis, phosphodiesterase type 5 Inhibitor, and quinine.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hebert-Lalonde N, et al. Electrophysiological evidences of visual field alterations in children exposed to vigabatrin early in life. Pediatr Neurol. 2016;59:47–53.

    Article  PubMed  Google Scholar 

  2. Tao Y, et al. The vigabatrin induced retinal toxicity is associated with photopic exposure and taurine deficiency: an in vivo study. Cell Physiol Biochem. 2016;40(5):831–46.

    Article  CAS  PubMed  Google Scholar 

  3. Kjellstrom U, Andreasson S, Ponjavic V. Attenuation of the retinal nerve fibre layer and reduced retinal function assessed by optical coherence tomography and full-field electroretinography in patients exposed to vigabatrin medication. Acta Ophthalmol. 2014;92(2):149–57.

    Article  PubMed  CAS  Google Scholar 

  4. Ruether K, et al. Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin. Arch Ophthalmol. 1998;116(6):817–9.

    CAS  PubMed  Google Scholar 

  5. Harding GF, et al. Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction. Epilepsia. 2000;41(11):1420–31.

    Article  CAS  PubMed  Google Scholar 

  6. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ. 1997;314(7075):180–1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Gross-Tsur V, et al. Visual impairment in children with epilepsy treated with vigabatrin. Ann Neurol. 2000;48(1):60–4.

    Article  CAS  PubMed  Google Scholar 

  8. Daneshvar H, et al. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology. 1999;106(9):1792–8.

    Article  CAS  PubMed  Google Scholar 

  9. Schroeder CE, et al. Effects of high-dose gamma-vinyl GABA (vigabatrin) administration on visual and somatosensory evoked potentials in dogs. Epilepsia. 1992;33 Suppl 5:S13–25.

    CAS  PubMed  Google Scholar 

  10. Cosi V, et al. Effects of vigabatrin on evoked potentials in epileptic patients. Br J Clin Pharmacol. 1989;27(Suppl 1):61S–8S.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Ponjavic V, Andreasson S. Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication. Doc Ophthalmol. 2001;102(1):63–72.

    Article  CAS  PubMed  Google Scholar 

  12. Yang J, et al. Vigabatrin-induced retinal toxicity is partially mediated by signaling in rod and cone photoreceptors. PLoS One. 2012;7(8):e43889.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Vogel KR, et al. mTOR inhibition mitigates molecular and biochemical alterations of vigabatrin-induced visual field toxicity in mice. Pediatr Neurol. 2017;66:44–52 e1.

    Article  PubMed  Google Scholar 

  14. Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum. 1993;23(2 Suppl 1):82–91.

    Article  CAS  PubMed  Google Scholar 

  15. Hobbs HE, Sorsby A, Freedman A. Retinopathy following chloroquine therapy. Lancet. 1959;2(7101):478–80.

    Article  CAS  PubMed  Google Scholar 

  16. Shearer RV, Dubois EL. Ocular changes induced by long-term hydroxychloroquine (plaquenil) therapy. Am J Ophthalmol. 1967;64(2):245–52.

    Article  CAS  PubMed  Google Scholar 

  17. Ivanina TA, et al. A study of the mechanisms of chloroquine retinopathy. II. Chloroquine effect on protein synthesis of retina. Ophthalmic Res. 1989;21(3):272–7.

    Article  CAS  PubMed  Google Scholar 

  18. Gonasun LM, Potts AM. In vitro inhibition of protein synthesis in the retinal pigment epithelium by chloroquine. Investig Ophthalmol. 1974;13(2):107–15.

    CAS  Google Scholar 

  19. Ivanina TA, et al. A study of the mechanisms of chloroquine retinopathy. I. Chloroquine effect on lipid peroxidation of retina. Ophthalmic Res. 1989;21(3):216–20.

    Article  CAS  PubMed  Google Scholar 

  20. Marmor MF, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123(6):1386–94.

    Article  PubMed  Google Scholar 

  21. Maturi RK, Yu M, Weleber RG. Multifocal electroretinographic evaluation of long-term hydroxychloroquine users. Arch Ophthalmol. 2004;122(7):973–81.

    Article  CAS  PubMed  Google Scholar 

  22. Pasadhika S, Fishman GA. Effects of chronic exposure to hydroxychloroquine or chloroquine on inner retinal structures. Eye (Lond). 2010;24(2):340–6.

    Article  CAS  Google Scholar 

  23. So SC, et al. Evaluation of hydroxychloroquine retinopathy with multifocal electroretinography. Ophthalmic Surg Lasers Imaging. 2003;34(3):251–8.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Michaelides M, et al. Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. Arch Ophthalmol. 2011;129(1):30–9.

    Article  CAS  PubMed  Google Scholar 

  25. Kellner U, Kraus H, Foerster MH. Multifocal ERG in chloroquine retinopathy: regional variance of retinal dysfunction. Graefes Arch Clin Exp Ophthalmol. 2000;238(1):94–7.

    Article  CAS  PubMed  Google Scholar 

  26. Lai TY, et al. Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy. Am J Ophthalmol. 2005;140(5):794–807.

    Article  PubMed  Google Scholar 

  27. Chang WH, et al. A novel method for screening the multifocal electroretonogram in patients using hydroxychloroquine. Retina. 2008;28(10):1478–86.

    Article  PubMed  Google Scholar 

  28. Lyons JS, Severns ML. Using multifocal ERG ring ratios to detect and follow Plaquenil retinal toxicity: a review: review of mfERG ring ratios in Plaquenil toxicity. Doc Ophthalmol. 2009;118(1):29–36.

    Article  PubMed  Google Scholar 

  29. Tsang AC, et al. Hydroxychloroquine and chloroquine retinopathy: a systematic review evaluating the multifocal electroretinogram as a screening test. Ophthalmology. 2015;122(6):1239–1251 e4.

    Article  PubMed  Google Scholar 

  30. Moschos MN, et al. Assessing hydroxychloroquine toxicity by the multifocal ERG. Doc Ophthalmol. 2004;108(1):47–53.

    Article  PubMed  Google Scholar 

  31. Tzekov RT, Serrato A, Marmor MF. ERG findings in patients using hydroxychloroquine. Doc Ophthalmol. 2004;108(1):87–97.

    Article  PubMed  Google Scholar 

  32. Nair AA, Marmor MF. ERG and other discriminators between advanced hydroxychloroquine retinopathy and retinitis pigmentosa. Doc Ophthalmol. 2017;134(3):175–83.

    Article  PubMed  Google Scholar 

  33. Marmor MF, et al. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118(2):415–22.

    Article  PubMed  Google Scholar 

  34. Young B, Eggenberger E, Kaufman D. Current electrophysiology in ophthalmology: a review. Curr Opin Ophthalmol. 2012;23(6):497–505.

    Article  PubMed  Google Scholar 

  35. Farrell DF. Retinal toxicity to antimalarial drugs: chloroquine and hydroxychloroquine: a neurophysiologic study. Clin Ophthalmol. 2012;6:377–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Nebbioso M, et al. Retina in rheumatic diseases: standard full field and multifocal electroretinography in hydroxychloroquine retinal dysfunction. Clin Exp Optom. 2011;94(3):276–83.

    Article  PubMed  Google Scholar 

  37. Nebbioso M, Grenga R, Karavitis P. Early detection of macular changes with multifocal ERG in patients on antimalarial drug therapy. J Ocul Pharmacol Ther. 2009;25(3):249–58.

    Article  CAS  PubMed  Google Scholar 

  38. Bartel P, et al. Effects of chlorpromazine on pattern and flash ERGs and VEPs compared to oxazepam and to placebo in normal subjects. Electroencephalogr Clin Neurophysiol. 1990;77(5):330–9.

    Article  CAS  PubMed  Google Scholar 

  39. Neves MS, Jordon K, Dragt H. Extensive chorioretinopathy associated with very low dose thioridazine. Eye (Lond). 1990;4(Pt 5):767–70.

    Article  Google Scholar 

  40. Hagopian V, Stratton DB, Busiek RD. Five cases of pigmentary retinopathy associated with thioridazine administration. Am J Psychiatry. 1966;123(1):97–100.

    Article  CAS  PubMed  Google Scholar 

  41. Kozy D, Doft BH, Lipkowitz J. Nummular thioridazine retinopathy. Retina. 1984;4(4):253–6.

    Article  CAS  PubMed  Google Scholar 

  42. Persad S, et al. Phototoxicity of chlorpromazine on retinal pigment epithelial cells. Curr Eye Res. 1988;7(1):1–9.

    Article  CAS  PubMed  Google Scholar 

  43. Richa S, Yazbek JC. Ocular adverse effects of common psychotropic agents: a review. CNS Drugs. 2010;24(6):501–26.

    Article  CAS  PubMed  Google Scholar 

  44. Katz BJ, et al. Persistent severe visual and electroretinographic abnormalities after intravenous Cisplatin therapy. J Neuroophthalmol. 2003;23(2):132–5.

    Article  PubMed  Google Scholar 

  45. Marmor MF. Negative-type electroretinogram from cisplatin toxicity. Doc Ophthalmol. 1993;84(3):237–46.

    Article  CAS  PubMed  Google Scholar 

  46. Wilding G, et al. Retinal toxicity after high-dose cisplatin therapy. J Clin Oncol. 1985;3(12):1683–9.

    Article  CAS  PubMed  Google Scholar 

  47. Simon S, et al. Desferrioxamine-related ocular toxicity: a case report. Indian J Ophthalmol. 2012;60(4):315–7.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Kaplinsky C, et al. Deferoxamine (Desferal)-induced ocular toxicity. Pediatr Hematol Oncol. 1988;5(4):293–7.

    Article  CAS  PubMed  Google Scholar 

  49. Haimovici R, et al. The expanded clinical spectrum of deferoxamine retinopathy. Ophthalmology. 2002;109(1):164–71.

    Article  PubMed  Google Scholar 

  50. Schmidt D, Finke J. Bull’s-eye maculopathy with deferoxamine treatment. Klin Monatsbl Augenheilkd. 2004;221(3):204–9.

    Article  CAS  PubMed  Google Scholar 

  51. Kertes PJ, Lee TK, Coupland SG. The utility of multifocal electroretinography in monitoring drug toxicity: deferoxamine retinopathy. Can J Ophthalmol. 2004;39(6):656–61.

    Article  PubMed  Google Scholar 

  52. Lely AH, van Enter CH. Large-scale digitoxin intoxication. Br Med J. 1970;3(5725):737–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Butler VP Jr, et al. Digitalis-induced visual disturbances with therapeutic serum digitalis concentrations. Ann Intern Med. 1995;123(9):676–80.

    Article  PubMed  Google Scholar 

  54. Robertson DM, Hollenhorst RW, Callahan JA. Ocular manifestations of digitalis toxicity. Discussion and report of three cases of central scotomas. Arch Ophthalmol. 1966;76(5):640–5.

    Article  CAS  PubMed  Google Scholar 

  55. Lawrenson JG, et al. Acquired colour vision deficiency in patients receiving digoxin maintenance therapy. Br J Ophthalmol. 2002;86(11):1259–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Renard D, et al. Spectrum of digoxin-induced ocular toxicity: a case report and literature review. BMC Res Notes. 2015;8:368.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  57. Piltz JR, et al. Digoxin toxicity. Recognizing the varied visual presentations. J Clin Neuroophthalmol. 1993;13(4):275–80.

    CAS  PubMed  Google Scholar 

  58. Weleber RG, Shults WT. Digoxin retinal toxicity. Clinical and electrophysiological evaluation of a cone dysfunction syndrome. Arch Ophthalmol. 1981;99(9):1568–72.

    Article  CAS  PubMed  Google Scholar 

  59. Madreperla SA, Johnson MA, Nakatani K. Electrophysiologic and electroretinographic evidence for photoreceptor dysfunction as a toxic effect of digoxin. Arch Ophthalmol. 1994;112(6):807–12.

    Article  CAS  PubMed  Google Scholar 

  60. Landfried B, et al. Digoxin-induced retinal degeneration depends on rhodopsin. Cell Death Dis. 2017;8(3):e2670.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Kinoshita J, et al. Digoxin-induced reversible dysfunction of the cone photoreceptors in monkeys. Invest Ophthalmol Vis Sci. 2014;55(2):881–92.

    Article  CAS  PubMed  Google Scholar 

  62. Maehara S, et al. Detection of cone dysfunction induced by digoxin in dogs by multicolor electroretinography. Vet Ophthalmol. 2005;8(6):407–13.

    Article  PubMed  Google Scholar 

  63. Deeti S, O’Farrell S, Kennedy BN. Early safety assessment of human oculotoxic drugs using the zebrafish visualmotor response. J Pharmacol Toxicol Methods. 2014;69(1):1–8.

    Article  CAS  PubMed  Google Scholar 

  64. Kandel H, et al. Visual function in patients on ethambutol therapy for tuberculosis. J Ocul Pharmacol Ther. 2012;28(2):174–8.

    Article  CAS  PubMed  Google Scholar 

  65. Lai TY, et al. Multifocal electroretinogram demonstrated macular toxicity associated with ethambutol related optic neuropathy. Br J Ophthalmol. 2005;89(6):774–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Behbehani RS, et al. Multifocal ERG in ethambutol associated visual loss. Br J Ophthalmol. 2005;89(8):976–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Kardon RH, Morrisey MC, Lee AG. Abnormal multifocal electroretinogram (mfERG) in ethambutol toxicity. Semin Ophthalmol. 2006;21(4):215–22.

    Article  PubMed  Google Scholar 

  68. Lai TY, et al. Multifocal electroretinography changes in patients on ethambutol therapy. Eye (Lond). 2009;23(8):1707–13.

    Article  CAS  Google Scholar 

  69. Liu Y, et al. Multifocal electroretinographic abnormalities in ethambutol-induced visual loss. J Neuroophthalmol. 2008;28(4):278–82.

    Article  PubMed  Google Scholar 

  70. Graham CM, Blach RK. Indomethacin retinopathy: case report and review. Br J Ophthalmol. 1988;72(6):434–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Madke B, Prasad K, Kar S. Isotretinoin-induced night blindness. Indian J Dermatol. 2015;60(4):424.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Weleber RG, et al. Abnormal retinal function associated with isotretinoin therapy for acne. Arch Ophthalmol. 1986;104(6):831–7.

    Article  CAS  PubMed  Google Scholar 

  73. Mollan SP, et al. Does use of isotretinoin rule out a career in flying? Br J Ophthalmol. 2006;90(8):957–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Kannan NB, et al. Management of ocular siderosis: visual outcome and electroretinographic changes. J Ophthalmol. 2016;2016:7272465.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Mumcuoglu T, et al. An animal model (guinea pig) of ocular siderosis: histopathology, pharmacology, and electrophysiology. Curr Eye Res. 2015;40(3):314–20.

    Article  CAS  PubMed  Google Scholar 

  76. Faure C, et al. Functional and high resolution retinal imaging assessment in a case of ocular siderosis. Doc Ophthalmol. 2014;128(1):69–75.

    Article  PubMed  Google Scholar 

  77. Kuhn F, et al. Improvement of siderotic ERG. Eur J Ophthalmol. 1992;2(1):44–5.

    Article  CAS  PubMed  Google Scholar 

  78. Declercq SS. Desferrioxamine in ocular siderosis: a long-term electrophysiological evaluation. Br J Ophthalmol. 1980;64(8):626–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Declercq SS, Meredith PC, Rosenthal AR. Experimental siderosis in the rabbit: correlation between electroretinography and histopathology. Arch Ophthalmol. 1977;95(6):1051–8.

    Article  CAS  PubMed  Google Scholar 

  80. Gupta S, et al. Sensitivity of multifocal electroretinography (mfERG) in detecting siderosis. Can J Ophthalmol. 2015;50(6):485–90.

    Article  PubMed  Google Scholar 

  81. Schechner R, et al. A long term follow up of ocular siderosis: quantitative assessment of the electroretinogram. Doc Ophthalmol. 1990;76(3):231–40.

    Article  PubMed  Google Scholar 

  82. Schocket SS, Lakhanpal V, Varma SD. Siderosis from a retained intraocular stone. Retina. 1981;1(3):201–7.

    Article  CAS  PubMed  Google Scholar 

  83. Eltony SA, Abdelhameed SY. Effect of chronic administration of sildenafil citrate (Viagra) on the histology of the retina and optic nerve of adult male rat. Tissue Cell. 2017;49(2. Pt B):323–35.

    Article  CAS  PubMed  Google Scholar 

  84. Coca MN, et al. Bilateral posterior ischemic optic neuropathy associated with the use of Sildenafil for pulmonary hypertension. Can J Ophthalmol. 2016;51(3):e96–9.

    Article  PubMed  Google Scholar 

  85. Moschos MM, Nitoda E. Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction. Drug Des Devel Ther. 2016;8:3407–13.

    Article  PubMed  Google Scholar 

  86. Luu JK, et al. Acute effects of sildenafil on the electroretinogram and multifocal electroretinogram. Am J Ophthalmol. 2001;132(3):388–94.

    Article  CAS  PubMed  Google Scholar 

  87. Kinoshita J, et al. Sildenafil-induced reversible impairment of rod and cone phototransduction in monkeys. Invest Ophthalmol Vis Sci. 2015;56(1):664–73.

    Article  CAS  PubMed  Google Scholar 

  88. Nivison-Smith L, et al. Sildenafil alters retinal function in mouse carriers of retinitis pigmentosa. Exp Eye Res. 2014;128:43–56.

    Article  CAS  PubMed  Google Scholar 

  89. Jagle H, et al. Dose-dependency and time-course of electrophysiologic short-term effects of VIAGRA: a case study. Doc Ophthalmol. 2005;110(2–3):247–54.

    Article  PubMed  Google Scholar 

  90. Luke M, et al. Effects of phosphodiesterase type 5 inhibitor sildenafil on retinal function in isolated superfused retina. J Ocul Pharmacol Ther. 2005;21(4):305–14.

    Article  PubMed  Google Scholar 

  91. McKoy JM, et al. Sildenafil- and tadalafil-associated optic neuropathy: implications for men after prostate cancer treatment. Commun Oncol. 2009;6(2):78–80.

    Article  Google Scholar 

  92. Martins J, et al. Sildenafil acutely decreases visual responses in ON and OFF retinal ganglion cells. Invest Ophthalmol Vis Sci. 2015;56(4):2639–48.

    Article  CAS  PubMed  Google Scholar 

  93. Jung S, et al. Sildenafil improves functional and structural outcome of retinal injury following term neonatal hypoxia-ischemia. Invest Ophthalmol Vis Sci. 2016;57(10):4306–14.

    Article  CAS  PubMed  Google Scholar 

  94. Roy R, et al. Central serous chorioretinopathy following oral tadalafil intake. Clin Exp Optom. 2014;97(5):473–4.

    Article  PubMed  Google Scholar 

  95. Fraunfelder FW, Fraunfelder FT. Central serous chorioretinopathy associated with sildenafil. Retina. 2008;28(4):606–9.

    Article  PubMed  Google Scholar 

  96. Coscas F, et al. Optical coherence tomography in tadalafil-associated retinal toxicity. Eur J Ophthalmol. 2012;22(5):853–6.

    Article  PubMed  Google Scholar 

  97. Peter NM, Singh MV, Fox PD. Tadalafil-associated anterior ischaemic optic neuropathy. Eye (Lond). 2005;19(6):715–7.

    Article  CAS  Google Scholar 

  98. Egan R, Pomeranz H. Sildenafil (Viagra) associated anterior ischemic optic neuropathy. Arch Ophthalmol. 2000;118(2):291–2.

    CAS  PubMed  Google Scholar 

  99. Cunningham AV, Smith KH. Anterior ischemic optic neuropathy associated with viagra. J Neuroophthalmol. 2001;21(1):22–5.

    Article  CAS  PubMed  Google Scholar 

  100. Boshier A, Pambakian N, Shakir SA. A case of nonarteritic ischemic optic neuropathy (NAION) in a male patient taking sildenafil. Int J Clin Pharmacol Ther. 2002;40(9):422–3.

    Article  CAS  PubMed  Google Scholar 

  101. Dheer S, Rekhi GS, Merlyn S. Sildenafil associated anterior ischaemic optic neuropathy. J Assoc Physicians India. 2002;50:265.

    PubMed  Google Scholar 

  102. Pomeranz HD, et al. Sildenafil-associated nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 2002;109(3):584–7.

    Article  PubMed  Google Scholar 

  103. Gruhn N, Fledelius HC. Unilateral optic neuropathy associated with sildenafil intake. Acta Ophthalmol Scand. 2005;83(1):131–2.

    Article  PubMed  Google Scholar 

  104. Pomeranz HD, Bhavsar AR. Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (viagra): a report of seven new cases. J Neuroophthalmol. 2005;25(1):9–13.

    Article  PubMed  Google Scholar 

  105. Escaravage GK Jr, Wright JD Jr, Givre SJ. Tadalafil associated with anterior ischemic optic neuropathy. Arch Ophthalmol. 2005;123(3):399–400.

    Article  PubMed  Google Scholar 

  106. Bollinger K, Lee MS. Recurrent visual field defect and ischemic optic neuropathy associated with tadalafil rechallenge. Arch Ophthalmol. 2005;123(3):400–1.

    Article  PubMed  Google Scholar 

  107. Egan RA, Fraunfelder FW. Viagra and anterior ischemic optic neuropathy. Arch Ophthalmol. 2005;123(5):709–10.

    Article  PubMed  Google Scholar 

  108. Kim IG, Kim DY. Anterior ischemic optic neuropathy associated with udenafil. Korean J Ophthalmol. 2012;26(3):235–8.

    Article  PubMed  PubMed Central  Google Scholar 

  109. Moloney JB, Hillery M, Fenton M. Two year electrophysiology follow-up in quinine amblyopia. A case report. Acta Ophthalmol. 1987;65(6):731–4.

    Article  CAS  Google Scholar 

  110. Su D, et al. Quinine toxicity: multimodal retinal imaging and electroretinography findings. Retin Cases Brief Rep. 2017;11 Suppl 1:S102–6.

    Article  PubMed  Google Scholar 

  111. Gangitano JL, Keltner JL. Abnormalities of the pupil and visual-evoked potential in quinine amblyopia. Am J Ophthalmol. 1980;89(3):425–30.

    Article  CAS  PubMed  Google Scholar 

  112. Sato S. Toxic effects on the visual system of diaminodiphenoxybutane, quinine, and ethambutol in conscious dogs. Fundam Appl Toxicol. 1985;5(4):777–84.

    Article  CAS  PubMed  Google Scholar 

  113. Saeed MU, et al. Relatively spared central multifocal electroretinogram responses in acute quinine toxicity. BMJ Case Rep. 2011;2011.

    Google Scholar 

  114. Verdon W. Clinical electrophysiology in quinine induced retinal toxicity. Optom Vis Sci. 2008;85(1):17–26.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, University Hospitals Eye Institute, Cleveland, OH, USA

    Minzhong Yu

  2. Center for Retinal Degenerations and Ophthalmic Genetic Diseases, Duke University School of Medicine, Duke Eye Center, Department of Ophthalmology, Durham, NC, USA

    Alfonso Senatore, Alessandro Iannaccone & Wajiha Jurdi Kheir

  3. Moran Eye Center, University of Utah School of Medicine, Salt Lake City, UT, USA

    Donnell Creel

Authors
  1. Minzhong Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alfonso Senatore
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alessandro Iannaccone
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wajiha Jurdi Kheir
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Donnell Creel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Minzhong Yu .

Editor information

Editors and Affiliations

  1. Department of Ophthalmology, University Hospitals Eye Institute, Cleveland, OH, USA

    Minzhong Yu

  2. Moran Eye Center, University of Utah School of Medicine, Salt Lake City, UT, USA

    Donnell Creel

  3. Center for Retinal Degenerations and Ophthalmic Genetic Diseases, Duke University School of Medicine, Duke Eye Center, Department of Ophthalmology, Durham, NC, USA

    Alessandro Iannaccone

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Yu, M., Senatore, A., Iannaccone, A., Kheir, W.J., Creel, D. (2019). Characteristics of Visual Electrophysiology in Retinal Toxicities. In: Yu, M., Creel, D., Iannaccone, A. (eds) Handbook of Clinical Electrophysiology of Vision. Springer, Cham. https://doi.org/10.1007/978-3-030-30417-1_9

Download citation

Publish with us

Policies and ethics

Search

Navigation